Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature

Autor: Wolf-Henning Boehncke, Tobias Weberschock, Sylke-Monina Muller, Sandra Boehncke
Jazyk: angličtina
Rok vydání: 2007
Předmět:
medicine.medical_specialty
Urticaria
Gastrointestinal Diseases
Respiratory Tract Diseases
Adverse drug reaction
Cyclooxygenase 2 Inhibitors/*adverse effects/*therapeutic use
Hot Clinical Study
Hemorrhage
Dermatology
Cochrane Library
Respiratory Tract Diseases/chemically induced
Double-Blind Method
Hemorrhage/chemically induced
Internal medicine
medicine
Coxibs
Humans
ddc:610
Prospective Studies
Adverse effect
Rofecoxib
Randomized Controlled Trials as Topic
Inflammation
Cyclooxygenase 2 Inhibitors
business.industry
Gastrointestinal Diseases/chemically induced
Anti-Inflammatory Agents
Non-Steroidal
General Medicine
Valdecoxib
medicine.disease
Surgery
Intolerance
Tolerability
Inflammation/*drug therapy
Celecoxib
Anti-Inflammatory Agents
Non-Steroidal/adverse effects/therapeutic use
business
Etoricoxib
Non-steroidal anti-inflammatory drugs
medicine.drug
Zdroj: Archives of Dermatological Research
Archives of Dermatological Research, Vol. 299, No 4 (2007) pp. 169-175
ISSN: 1432-069X
0340-3696
Popis: Adverse events triggered by non-steroidal anti-inflammatory drugs (NSAIDs) are among the most common drug-related intolerance reactions in medicine; they are possibly related to inhibition of cyclooxygenase-1. Coxibs, preferentially inhibiting cyclooxygenase-2, may therefore represent safe alternatives in patients with NSAID intolerance. We reviewed the literature in a systematic and structured manner to identify and evaluate studies on the tolerance of coxibs in patients with NSAID intolerance. We searched MEDLINE (1966-2006), the COCHRANE LIBRARY (4th Issue 2006) and EMBASE (1966-2006) up to December 9, 2006, and analysed all publications included using a predefined evaluation sheet. Symptoms and severity of adverse events to coxibs were analysed based on all articles comprising such information. Subsequently, the probability for adverse events triggered by coxibs was determined on analyses of double-blind prospective trials only. Among 3,304 patients with NSAID intolerance, 119 adverse events occurred under coxib medication. All adverse events, except two, have been allergic/urticarial in nature; none was lethal, but two were graded as life-threatening (grade 4). The two non-allergic adverse events were described as a grade 1 upper respiratory tract haemorrhage, and a grade 1 gastrointestinal symptom, respectively. In 13 double-blind prospective studies comprising a total of 591 patients with NSAID intolerance, only 13 adverse reactions to coxib provocations were observed. The triggering coxibs were rofecoxib (2/286), celecoxib (6/208), etoricoxib (4/56), and valdecoxib (1/41). This review documents the good tolerability of coxibs in patients with NSAID intolerance, for whom access to this class of drugs for short-term treatment of pain and inflammation is advantageous.
Databáze: OpenAIRE
Externí odkaz: